Home » Authors » Aaron Lorenzo

Articles by Aaron Lorenzo

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint

Aug. 31, 2006

By Aaron Lorenzo

OrthoLogic's Stock Dips As Phase IIb Misses Endpoint

Aug. 31, 2006

By Aaron Lorenzo

SGX Stock Plummets After Troxatyl Fails In Phase II/III

Aug. 30, 2006

By Aaron Lorenzo

Shares in SGX Pharmaceuticals Inc. suffered mightily on Tuesday following a Phase II/III study stoppage. (BioWorld Today)

SGX Stock Plummets After Troxatyl Fails In Phase II/III

Aug. 30, 2006

By Aaron Lorenzo

Shares in SGX Pharmaceuticals Inc. suffered mightily on Tuesday following a Phase II/III study stoppage. (BioWorld Today)

EPIX's Contrast Agent Vasovist Dealt Another Setback By FDA

Aug. 29, 2006

By Aaron Lorenzo

EPIX's Contrast Agent Vasovist Dealt Another Setback By FDA

Aug. 29, 2006

By Aaron Lorenzo

FDA, MIT Working On Better Post-Approval Safety System

Aug. 21, 2006

By Aaron Lorenzo

FDA, MIT Working On Better Post-Approval Safety System

Aug. 21, 2006

By Aaron Lorenzo

Biotechs Should Benefit When Leadership Atop FDA Finalized

Aug. 18, 2006

By Aaron Lorenzo

Biotechs Should Benefit When Leadership Atop FDA Finalized

Aug. 18, 2006

By Aaron Lorenzo

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 24, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 24, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
HIV research is close to a cure but far from ending the pandemic
BioWorld
Advances in antiretroviral therapy (ART) now allow people living with HIV to lead normal lives with undetectable and nontransmissible levels of the virus in their...
ADEL wins $1.04B Sanofi deal for tau-targeting Alzheimer’s drug
BioWorld
ADEL Inc. closed a year-end licensing deal worth up to $1.04 billion with Sanofi SA for ADEL-Y01, a specific tau-targeting Alzheimer’s disease drug candidate in a...